CTRI/2024/07/070855尚未招募3 期
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer. - NI
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- Tolmar, Inc.
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Able to understand the investigational nature of this study and provide written informed consent prior to the participation in the trial.
- •2. Age 18 to 49, inclusive.
- •3. Diagnosis of Stage I, II, or III HR+, HER2-negative breast cancer (ER greater than 1 percent and/or, PR greater than 1 percent, HER2-negative per ASCO CAP guidelines).
- •4. Is a candidate for endocrine therapy + ovarian suppression LH greater than 4 IU per L within 28 days prior to Day 1.
- •5. Is premenopausal as defined by
- •E2 greater than 30 pg per mL
- •follicle-stimulating hormone (FSH) less than 40 IU per L
- •regular menses (eg, menstrual cycle length of 21 to 35 days) Note: premenopausal status must be determined before neo or adjuvant chemotherapy in patients for which it is planned or prior to Day 1 in patients who did not have prior chemotherapy. If premenopausal status was not determined prior to chemotherapy, E2 and FSH must meet the above criteria when measured 2 weeks or more after the end of the final cycle of chemotherapy.
排除标准
- •1. Body mass index (BMI) less than 18.00 kg per m2 or greater than 35.00 kg per m2
- •2. Breastfeeding
- •3. Life expectancy less than 12 months
- •4. Eastern Cooperative Oncology Group (ECOG) performance status greater than or equal to 3
- •5. Unacceptable hepatic function as determined by any of the following:
- •a. Alanine aminotransferase (ALT) greater than or equal to 2X upper limit of normal (ULN)
- •b. Aspartate aminotransferase (AST) greater than or equal to 2X ULN
- •c. Bilirubin greater than or equal to 2X ULN
- •d. Alkaline phosphatase greater than or equal to 2X ULN
- •e. Severe hepatic impairment (Child-Pugh Class C)
- •6. Unacceptable renal function as determined by any of the following:
- •a. Creatinine greater than or equal to 3X ULN
- •b. Creatinine clearance less than or equal to 30 mL per minute
- •c. Creatinine clearance less than or equal to 60 mL per minute in subjects with bone density 1.5 standard deviations below the young adult normal mean
- •7. History of significantly abnormal ECG or screening 12-lead ECG demonstrating any of the following:
- •a. HR greater than 100 BPM
- •b. QRS greater than 120 msec
- •c. QTc greater than 450 msec
- •d. PR greater than 220 msec
- •8. Prior (within 28 days prior to Day 1) and/or concomitant use of medications known to prolong the QT/QTc interval
- •9. Prior use of tamoxifen, other SERMs (eg, raloxifene) or antagonists (eg, fulvestrant), aromatase inhibitor, mammalian target of rapamycin (mTOR) inhibitors, or hormone replacement therapy within 3 months before breast cancer diagnosis
- •10. Concomitant use of anticancer mediations other than those specified for use by the protocol
- •11. Prior neoadjuvant or adjuvant endocrine therapy since diagnosis of breast cancer
- •12. History of treatment for osteopenia/osteoporosis or baseline bone mineral density Z-scoreless than or equal to -2.0
- •13. Prior (within 6 months prior to Day 1) or current use of drugs known to increase bone mineral density (ie, bisphosphonates, denosumab, teriparatide, abaloparatide, romosozumab) or use of supplements known to increase bone mineral density (ie, calcitonin, fluoride, strontium) within 28 days prior to Day 1
- •14. Low trauma fracture(s) occurring within 12 months prior to subject’s first visit (defined as a fracture that results from a fall from a standing height or less, excluding fingers, toes, face and skull)
- •15. Conditions that preclude bone mineral density measurement (lumbar spine/bilateral hip surgery with hardware in place, abdominal clips, umbilical ring [not willing to remove] or weight that exceeds the DEXA machine limitation)
- •16. Any other medical condition or serious illness, presence of a second malignancy under current treatment or follow-up, or the presence of clinically significant findings on the physical exam, laboratory testing, medical history (including conditions that may be associated with low bone mass), that in the opinion of the Investigator may interfere with trial conduct, subject safety, or interpretation of study results
- •17. Already receiving and/or previously received GnRH analogs within 1 year before breast cancer diagnosis
- •18. Psychiatric, addictive, or other disorders that would preclude study compliance
- •19. Use of medications that may impact subject safety and/or affect the PK of the drug and hormonal assessments includin
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 study to evaluate the efficacy and safety of BMN 270 gene transfer in patients with severe hemophilia AHaemophilia AMedDRA version: 20.0Level: LLTClassification code 10060612Term: Hemophilia ASystem Organ Class: 100000004850EUCTR2017-003215-19-FRBioMarin Pharmaceutical Inc.130
进行中（未招募）
1 期
A Phase 3 study to evaluate the efficacy and safety of BMN 270 gene transfer in patients with severe hemophilia AHaemophilia AMedDRA version: 20.0Level: LLTClassification code 10060612Term: Hemophilia ASystem Organ Class: 100000004850EUCTR2017-003215-19-DEBioMarin Pharmaceutical Inc.134
进行中（未招募）
1 期
A Phase 3 study to evaluate the efficacy and safety of BMN 270 gene transfer in patients with severe hemophilia AHaemophilia AEUCTR2017-003215-19-GBBioMarin Pharmaceutical Inc.134
进行中（未招募）
1 期
A Phase 3 study to evaluate the efficacy and safety of BMN 270 gene transfer in patients with severe hemophilia AHaemophilia AEUCTR2017-003573-34-ESBioMarin Pharmaceutical Inc.70
进行中（未招募）
1 期
A Phase 3 study to evaluate the efficacy and safety of BMN 270 gene transfer in patients with severe hemophilia AHaemophilia AEUCTR2017-003573-34-GBBioMarin Pharmaceutical Inc.70